Adjuvant pembrolizumab continues to demonstrate DFS benefit in renal cell carcinoma - Urology Times
“I think that this updated analysis of KEYNOTE-564 further supports adjuvant pembrolizumab as a new standard of care for patients with RCC with high risk of recurrence,” said Toni K. Choueiri, MD.
An updated analysis of the phase 3 KEYNOTE-564 trial (NCT03142334) found that adjuvant treatment with pembrolizumab (Keytruda) continued to demonstrate improved disease-free survival (DFS) vs placebo… [+3668 chars]
Read More
Other Stories in Business
- Gulf War veteran executed for 1998 quadruple murder despite claims of mental illness
- Guardant Health (GH) Reports Strong Q1 2025 Revenue Growth
- Connecting Asia's startup ecosystem
- Connecting Asia's startup ecosystem
- From a Joke That Went Too Far to Radical Ideology – How Did the Memecoin Paradigm Change
- From a Joke That Went Too Far to Radical Ideology – How Did the Memecoin Paradigm Change
- L3Harris Technologies Stock: A Steady Course In A Changing World (NYSE:LHX)
- L3Harris Technologies Stock: A Steady Course In A Changing World (NYSE:LHX)
- Business First Bancshares, Inc. (BFST) Q1 2025 Earnings Call Transcript
